Introduction {#tca12794-sec-0005}
============

In the past decade, esophageal carcinoma, which involves a poor prognosis, has become the sixth most common cancer.[1](#tca12794-bib-0001){ref-type="ref"} The main histological types of esophageal cancer include squamous cell carcinoma and adenocarcinoma, and \> 95% esophageal cancers are located in the non‐cervical esophagus.[2](#tca12794-bib-0002){ref-type="ref"} Treatment strategies are similar for both types of esophageal cancer, and include surgery, chemotherapy, and radiotherapy. For early stage and thoracic or abdominal esophageal cancer, surgical resection is the primary option, while definitive chemoradiotherapy is utilized more often in advanced or cervical esophageal cancer. Currently, neoadjuvant chemoradiotherapy (NCRT) has gradually gained clinical acceptance, but has the potential for degrading the staging of primary tumors, and is thus controversial, especially neoadjuvant radiotherapy (NRT).[3](#tca12794-bib-0003){ref-type="ref"} Though NRT can reduce the size of a local tumor and make it possible to perform surgery, NRT might also increase the risk of postoperative complications, which are associated with a poor prognosis.[4](#tca12794-bib-0004){ref-type="ref"} Furthermore, the stage of non‐cervical esophageal cancer that would result in a greater benefit from NRT has not been established, and no research based on a large population has determined the correlation between NRT and prognosis in patients with esophageal cancer. All these factors limit the application of NRT in the treatment of non‐cervical esophageal cancer, and additional evidence is needed to demonstrate its effects.

Propensity score‐matched (PSM) analysis, which was defined by Rosenbaum and Robin[5](#tca12794-bib-0005){ref-type="ref"} and has been increasingly applied to medical research, is a method for reducing treatment selection bias by adjusting for variables related to exposure and pretreatment confounding, which might affect outcomes in non‐randomized studies. In the current study we compared the overall survival of patients with thoracic or abdominal esophageal squamous cell carcinoma (ESCC)/esophageal adenocarcinoma (EAC) who underwent surgery with or without NRT based on the data from the Surveillance Epidemiology, and End Results \[SEER (<http://seer.cancer.gov>/)\] database after applying the PSM method to provide evidence for NRT in the treatment of esophageal cancer.

Patients and Methods {#tca12794-sec-0006}
====================

Study population {#tca12794-sec-0007}
----------------

The data used in the current study was selected from the SEER database, which is freely available to the public (<https://seer.cancer.gov/>). The SEER program of the National Cancer Institute is an authoritative source of information on the incidence and prevalence of cancer, mortality rates, population‐based variables, primary tumor characteristics, and treatment, and covers approximately 28% of the US population.

SEER\*Stat software was used to screen the population for the current study. The patients with T~2~ and T~3~ stage non‐cervical esophageal cancer who had accurate TNM records and underwent surgical resection between 2004 and 2014 were enrolled in the study. We did not include T~1~ and T~4~ stages that lacked adequate statistics in this research. Patients who did not undergo radical surgery or did not have ESCC nor EAC histological types were excluded from the study. Patients with M~1~ stage or patients who underwent peri‐ or postoperative radiotherapy were also excluded. Information on age, sex, race, marital status, insurance status, primary site of tumor, pathological grade, histological type, TNM stage, radiotherapy status, and survival were collected for each case from the SEER database. The 7th edition of the TNM staging system for esophageal cancer was used as a reference in the study.[6](#tca12794-bib-0006){ref-type="ref"}

Statistical analysis {#tca12794-sec-0008}
--------------------

All cases were divided into two groups on the basis of histological types (ESCC and EAC), and split into two subgroups by the presence or absence of NRT. Each pair of subgroups was matched for other baseline variables, which would confound comparisons by PSM. These variables included age, sex, race, marital status, insurance status, primary site of tumor, pathologic grade, T stage and lymph node involvement status. All cases in both groups with NRT plus surgery (NRS) were matched at a 2:1 ratio to cases with surgery alone (SA) using the nearest neighbor match method with a 0.1 standard deviation caliper width.[7](#tca12794-bib-0007){ref-type="ref"}

Survival curves of the presence or absence of NRT for T~2~ and T~3~ stages in the ESCC and EAC groups were evaluated using the Kaplan‐Meier method. Furthermore, according to positive or negative pathological involvement of lymph nodes in T~2~ and T~3~ stages, we drew another two pairs of survival curves. Each pair of curves were compared using the stratified log‐rank test and a *P*‐value \<0.05 was considered to represent statistical significance. PSM analysis was performed using the MatchIt package (<https://cran.r-project.org/web/packages/MatchIt/index>), while the Kaplan‐Meier method and log‐rank test were performed using the survival package in R project 3.4.2 (<http://www.r-project.org>). SPSS 24.0 software (IBM Corporation, Armonk, NY, USA) was used for the remaining statistical analyses.

Results {#tca12794-sec-0009}
=======

A group of 8797 patients with esophageal cancer and TNM stage records who underwent beam radiation between 2004--2014 were identified by SEER\*Stat. A total of 1631 patients, which included 345 patients with ESCC and 1286 patients with EAC were enrolled in the study after selection. The selection process is shown in Fig [1](#tca12794-fig-0001){ref-type="fig"}.

![The flow diagram of the selection process for the study.](TCA-9-1111-g001){#tca12794-fig-0001}

Propensity score‐matching {#tca12794-sec-0010}
-------------------------

Based on the original data, 252 patients (73.0%) with ESCC and 1070 patients (83.2%) with EAC underwent NRT. Among the ESCC patients, the distribution of NRS and SA showed a statistical significance in T and N stage and insurance status. A similar difference in distribution was detected with respect to age, T and N stage, insurance status, and marital status in patients with EAC. In both the ESCC and EAC groups, all characteristics not included in the Kaplan‐Meier survival analysis were matched by PSM between the NRS and SA subgroups at a 2:1 ratio. The mirror histograms of propensity scores for patients stratified by therapy status were shown in Fig [2](#tca12794-fig-0002){ref-type="fig"}. The distribution of these baseline variables was appropriately balanced in the matched data set, which was detected by chi‐square testing for both the ESCC (Table [1](#tca12794-tbl-0001){ref-type="table"}) and EAC groups (Table [2](#tca12794-tbl-0002){ref-type="table"}). All of the significant differences in the aforementioned distribution were decreased after matching, and chi‐square testing in each line list of baseline characteristics showed a *P*‐value \>0.05. Additionally, the balance in the baseline variables in both original data set and matched data set were validated by limited standardized difference.[8](#tca12794-bib-0008){ref-type="ref"} Finally, 225 patients with ESCC and 606 patients with EAC were enrolled in survival analysis.

![The mirror histograms of propensity scores for cases with NRS (above the horizontal line at zero) and SA (below the horizontal line at zero) in group of ESCC (**a**) and EAC (**b**). Matched cases are a subset of original data and their volumes are highlighted. NRS, neoadjuvant radiotherapy plus surgery; SA, surgery alone.](TCA-9-1111-g002){#tca12794-fig-0002}

###### 

Comparison of baseline variables between NRS and SA groups in the original and matched data sets in cases of ESCC

                               Original Data Set   Matched Data Set                                                     
  --------------------------- ------------------- ------------------ --------- ------- ------------ ----------- ------- -------
  Total                               252                 93                               150          75              
  Age(year)                                                                    0.163                                    0.108
  \<60                            102 (40.5)           30(32.3)      0.172               44(29.3)    30(40.0)   0.186   
  ≥60                             150 (59.5)           63(67.7)      0.172              106(70.7)    45(60.0)   0.186   
  Gender                                                                       0.334                                    0.848
  Male                            158 (62.7)          53 (57.0)      0.096              90 (60.0)    44 (58.7)  0.022   
  Female                           94 (37.3)          40 (43.0)      0.096              60 (40.0)    31 (41.3)  0.022   
  Race                                                                         0.625                                    0.749
  White                           187 (74.2)          63 (67.7)      0.118              111 (74.0)   54 (72.0)  0.036   
  Others                           65 (25.8)          30 (32.3)      0.118              39 (26.0)    21 (28.0)  0.036   
  Insurance status                                                             0.043                                    1.000
  Insured                         178 (70.7)          55 (59.1)      0.201              102 (68.0)   51 (68.0)  0.000   
  Others                           74 (29.4)          38 (40.9)      0.201              48 (32.0)    24 (32.0)  0.000   
  Marital status                                                               0.514                                    0.924
  Married                         140 (55.6)          48 (51.6)      0.065              85 (56.7)    42 (56.0)          
  Others                          112 (44.4)          45 (48.4)      0.065              65 (43.3)    33 (44.0)          
  Primary site                                                                 0.712                                    0.777
  Thoracic                        133 (52.8)          47 (50.5)      0.036              77 (51.3)    40 (53.3)  0.032   
  Abdominal                       119 (47.2)          46 (49.5)      0.036              73 (48.7)    35 (46.7)  0.032   
  Pathologic grade                                                             0.633                                    0.785
  I                                16 (6.4)            9 (9.7)       0.123               8 (5.3)      5 (6.7)   0.056   
  II                              141 (56.0)          49 (52.7)      0.066              91 (60.7)    42 (56.0)  0.049   
  III                              94 (37.3)          34 (36.6)      0.015              50 (33.3)    28 (37.3)  0.008   
  IV                                1 (0.4)            1 (1.1)       0.078               1 (0.7)       0 (0)    0.015   
  T stage                                                                      0.008                                    0.478
  T2                               59 (23.4)          35 (37.6)      0.126              45 (30.0)    26 (34.7)  0.082   
  T3                              193 (76.6)          58 (62.4)      0.126              105 (70.0)   49 (65.3)  0.082   
  Involvement of lymph node                                          \<0.001                                    0.396   
  Negative                         96 (38.1)          58 (62.4)      0.408              71 (47.3)    40 (53.3)  0.098   
  Positive                        156 (61.9)          35 (37.6)      0.408              79 (52.7)    35 (46.7)  0.098   

*P* value for chi‐square test.

NRS, Neoadjuvant radiotherapy plus surgery; SA, Surgery alone; Sdiff, Standardized differences.

###### 

Comparison of baseline variables between NRS and SA groups in the original and matched data sets in cases of EAC

                               Original Data Set   Matched Data Set                                                      
  --------------------------- ------------------- ------------------ ------- --------- ------------ ------------ ------- -------
  Total                              1070                216                               404          202              
  Age (year)                                                                 0.006                                       0.896
  \<60                            366 (34.2)          53 (24.5)      0.171              104 (25.7)   53 (26.2)   0.009   
  ≥60                             704 (65.8)          163 (75.5)     0.171              300 (74.3)   149 (73.8)  0.009   
  Gender                                                                     0.225                                       0.649
  Male                            970 (90.7)          190 (88.0)     0.072              357 (88.4)   181 (89.6)  0.032   
  Female                           100 (9.3)          26 (12.0)      0.072              47 (11.6)    21 (10.4)   0.032   
  Race                                                                       0.165                                       0.065
  White                           1028 (96.1)         203 (94.0)     0.081              391 (96.8)   189 (93.6)  0.036   
  Others                           42 (3.9)            13 (6.0)      0.081               13 (3.2)     13 (6.4)   0.036   
  Insurance status                                                           0.019                                       0.419
  Insured                         828 (77.4)          151 (69.9)     0.141              275 (68.1)   144 (71.3)  0.056   
  Others                          242 (22.6)          65 (30.1)      0.141              129 (31.9)   58 (28.7)   0.056   
  Marital status                                                             0.032                                       0.681
  Married                         725 (67.8)          130 (60.2)     0.130              241 (59.7)   124 (61.4)  0.028   
  Others                          345 (32.2)          86 (39.8)      0.130              163 (40.3)   78 (38.6)   0.028   
  Primary site                                                               0.978                                       0.248
  Thoracic                         54 (5.1)            11 (5.1)      0.268               14 (3.5)     11 (5.4)   0.081   
  Abdominal                       1016 (94.9)         205 (94.9)     0.268              390 (96.5)   191 (94.6)  0.081   
  Pathologic grade                                                           \<0.001                                     0.887
  I                                61 (5.7)            14 (6.5)      0.030               21 (5.2)     13 (6.4)   0.025   
  II                              468 (43.7)          88 (40.7)      0.069              174 (43.1)   84 (41.6)   0.030   
  III                             530 (49.5)          109 (50.5)     0.028              203 (50.3)   101 (50.0)  0.005   
  IV                               11 (1.0)            5 (2.3)       0.100               6 (1.5)      4 (2.0)    0.037   
  T stage                                                                    \<0.001                                     0.534
  T2                              212 (19.8)          70 (32.4)      0.243              128 (31.7)   59 (29.2)   0.044   
  T3                              858 (80.2)          146 (67.6)     0.243              276 (68.3)   143 (70.8)  0.044   
  Involvement of lymph node                                          0.002                                       0.719   
  Negative                        314 (29.4)          87 (40.3)      0.191              142 (35.2)   74 (36.6)   0.025   
  Positive                        756 (70.6)          129 (59.7)     0.191              262 (64.8)   128 (63.4)  0.025   

*P* value for chi‐square test.

NRS, neoadjuvant radiotherapy plus surgery; SA, surgery alone; Sdiff, standardized differences.

Survival analysis {#tca12794-sec-0011}
-----------------

The overall survival curves of NRS *versus* SA before and after matching are shown in Fig [2](#tca12794-fig-0002){ref-type="fig"}. No significant differences were detected in each pair of curves in the ESCC (Fig [3](#tca12794-fig-0003){ref-type="fig"}a,b) and EAC groups (Fig [3](#tca12794-fig-0003){ref-type="fig"}c,d). The overall survival curve of NRS was nearly in agreement with SA in the ESCC group. In the EAC group, the 1 and 2 year survivals of NRS were better than SA, but the two subgroups had a similar survival rate \> 3 years postoperatively.

![Overall Kaplan‐Meier survival curve according to (**a**) ESCC without PSM, (**b**) ESCC with PSM, (**c**) EAC without PSM and (**d**) EAC with PSM. NRS, neoadjuvant radiotherapy plus surgery; SA, surgery alone.](TCA-9-1111-g003){#tca12794-fig-0003}

To explore the relationship between NRS and stage of esophageal cancer, further survival analysis was carried out based on T~2~ and T~3~ stages. The Kaplan‐Meier curves and log‐rank test showed no statistical significance between the prognoses of ESCC patients with T~2~ and T~3~ stages who underwent NRS or SA (Fig [4](#tca12794-fig-0004){ref-type="fig"}a,b). In the EAC group, there was no significant difference in the T~2~ stage (Fig [4](#tca12794-fig-0004){ref-type="fig"}c); however, the T~3~ stage EAC patients would benefit from NRS (*P* = 0.011, Fig [4](#tca12794-fig-0004){ref-type="fig"}d).

![Overall Kaplan‐Meier survival curve according to different histological type and stage including (**a**) ESCC T~2~, (**b**) ESCC T~3~, (**c**) EAC T~2~ and (**d**) EAC T~3~. NRS, neoadjuvant radiotherapy plus surgery; SA, surgery alone.](TCA-9-1111-g004){#tca12794-fig-0004}

In consideration of the fact that it is difficult to examine positive lymph nodes without a pathological diagnosis of surgical specimens preoperatively, which leads to N stage confusion; the T stage was the only basis for primary grouping in the current study. It is easy to confirm positive involvement of lymph nodes by preoperative imaging, thus the status of lymph node involvement based on each T stage was divided into two parts (N~0~ and N~+~). A comparison of survival curves in each subgroup is shown in Fig [5](#tca12794-fig-0005){ref-type="fig"}, [6](#tca12794-fig-0006){ref-type="fig"}. NRS improves the prognosis of T~3~N~+~ stage of EAC (*P* = 0.0052. Fig [6](#tca12794-fig-0006){ref-type="fig"}d), while NRS showed no significant benefit in overall survival for the other subgroups (Fig [5](#tca12794-fig-0005){ref-type="fig"}a--d, [6](#tca12794-fig-0006){ref-type="fig"}a--c).

![Overall Kaplan‐Meier survival curve according to status of lymph node involvement in T~2~ and T~3~ stage of ESCC including (**a**) T~2~N~0~, (**b**) T~2~N~+~, (**c**) T~3~N~0~ and (**d**) T~3~N~+~. NRS, neoadjuvant radiotherapy plus surgery; SA, surgery alone.](TCA-9-1111-g005){#tca12794-fig-0005}

![Overall Kaplan‐Meier survival curve according to status of lymph node involvement in T~2~ and T~3~ stage of EAC including (**a**) T~2~N~0~, (**b**) T~2~N~+~, (**c**) T~3~N~0~ and (**d**) T~3~N~+~.](TCA-9-1111-g006){#tca12794-fig-0006}

Discussion {#tca12794-sec-0012}
==========

This study focused on comparing the prognosis of patients who had undergone esophagectomy alone *versus* surgery with NRT in patients with non‐cervical ESCC and EAC T~2~ and T~3~ stages based on a large sample size and the PSM method. Finally, we found that NRT was only associated with a better prognoses in patients with EAC T~3~N~+~ stage. Compared with surgical resection alone, another analysis showed that the overall survival in ESCC and other stages of EAC did not benefit from NRT.

However, there is several major limitations in this manuscript that should be noted. Since the preoperative chemotherapy details were not recorded in SEER database, some of the patients analyzed in our manuscript might also have received neoadjuvant chemotherapy. NRT strategy was not recommended by North American, Europe, or Japanese guidelines, therefore it is likely that the NRT patients might have some unmeasured confounders, just like comorbidity or body weight loss, which made their treatment physicians chose the non‐recommended NRT instead of recommended NCRT. These unmeasured confounders made the analyses in the current manuscript biased and the results must be further validated.

In recent decades, a small number of studies have focused on the effect of NRT in patients with esophageal cancer. In a randomized clinical trial based on 206 thoracic ESCC patients, there was no advantage in 3 and 5 year survival compared to surgery alone.[9](#tca12794-bib-0009){ref-type="ref"} A clinical trial by Arnott *et al*.,[10](#tca12794-bib-0010){ref-type="ref"} including 56 patients with ESCC and 114 patients with EAC, also reported similar overall survival in patients who received NRT and those managed by SA. The result of two phase III trials also showed that NRT along with surgery had no value in improving resectability and overall survival in patients with esophageal cancer.[11](#tca12794-bib-0011){ref-type="ref"}, [12](#tca12794-bib-0012){ref-type="ref"} However, few studies have investigated the relationship between stage of esophageal cancer and NRT.

Currently, the majority of studies have compared the prognosis of NCRT with surgical resection *versus* SA. In combination with chemotherapy, NCRT has shown a potential survival benefit in a series of studies, but these studies were heterogenous in terms of histological type, tumor stage, and therapeutic regimens. In a phase III trial by Tepper *et al*.,[13](#tca12794-bib-0013){ref-type="ref"} cisplatin and fluorouracil concurrently with radiotherapy before resection reflected survival advantages in both ESCC and EAC patients. Another study by Walsh *et al*.[14](#tca12794-bib-0014){ref-type="ref"} reported that NCRT was superior to resection alone with a similar regimen. A generic regimen of neoadjuvant therapy for both ESCC and EAC was proposed by van Hagen *et al*. that included cisplatin and paclitaxel (six cycles) and concurrent radiotherapy (41.4 Gy) based on a trial with 368 patients.[15](#tca12794-bib-0015){ref-type="ref"} However, there are also several studies or clinical trials that have failed to demonstrate the statistical significance between NCRT and SA.[16](#tca12794-bib-0016){ref-type="ref"}, [17](#tca12794-bib-0017){ref-type="ref"}, [18](#tca12794-bib-0018){ref-type="ref"}

Only a few studies have focused on the correlation between NRT or NCRT and stage of esophageal cancer. For early stage esophageal cancer, a trial by Nygaad *et al*.[19](#tca12794-bib-0019){ref-type="ref"} involving 108 stage T~1~ and T~2~ ESCC patients did not show overall survival after NRT. A phase III trial based on 195 patients revealed that NCRT did not improve the R0 resection rate or survival, but increased the postoperative mortality in stage I and II esophageal cancer.[20](#tca12794-bib-0020){ref-type="ref"} Different results were obtained following NCRT in patients with advanced esophageal cancer. A study involving 193 patients with ESCC concluded that a pathological complete response to NCRT was critical for improving survival in T3 stage, while another study based on 214 patients with T~3~N~1~ EAC suggested that NCRT was not a significant determinant of overall survival or disease‐free survival.[21](#tca12794-bib-0021){ref-type="ref"}, [22](#tca12794-bib-0022){ref-type="ref"} Due to a lack of evidence, there was no consensus on which stage of esophageal cancer should be appropriate for neoadjuvant therapy.

Recently, the National Comprehensive Cancer Network (NCCN) guidelines for esophageal and esophagogastric junction cancer suggested that ESCC and EAC patients with T~1b~‐T~4a~, N~0~ to N~+~, and M~0~ stages receive preoperative chemoradiation, while the European Society for Medical Oncology (ESMO) guidelines showed that ESCC and EAC patients with T~3~ to T~4~ or N~1~ to N~3~ with M~0~ stages should undergo NCRT.[23](#tca12794-bib-0023){ref-type="ref"}, [24](#tca12794-bib-0024){ref-type="ref"} In the clinical guidelines edited by the Japan Esophageal Society, NCRT was not recommended as preoperative therapy for any histological type.[25](#tca12794-bib-0025){ref-type="ref"} In the current study, evidence of NRT for specific stages of esophageal cancer was provided. Unlike any guidelines mentioned, the results of this research suggested a limited benefit of NRT in EAC patients with esophageal cancer T3N+ stage, and NRT did not show an advantage in prognosis in any other stages. An accurate assessment for staging should be evaluated before neoadjuvant therapy.

Compared with SA, neoadjuvant therapy may add to the risk of toxicity. The potential complications, which included pneumonia, acute respiratory distress syndrome, anastomotic leakage, and cardiac complications, were mainly caused by radiotherapy.[26](#tca12794-bib-0026){ref-type="ref"} In a study of Bosch *et al*.,[27](#tca12794-bib-0027){ref-type="ref"} a significant increase in cardiopulmonary complications was observed in the neoadjuvant therapy group. Moreover, in a phase III trial, more postoperative deaths were demonstrated in patients treated by chemoradiotherapy preoperatively.[28](#tca12794-bib-0028){ref-type="ref"} Although postoperative radiation‐related complications would be reduced with the development of radiotherapy, such as application of stereotactic body radiation, it was also necessary to evaluate the cardiopulmonary function of patients for the design and modification of radiation dosage.[29](#tca12794-bib-0029){ref-type="ref"}

There are several other limitations in this study. Because preoperative radiation dose and postoperative complication data were not available in the SEER database, even though it was a population‐based database, we could not explore the relationship between dose and stage and compare the risk of complications in the PRS and SA groups. In addition, the current study was a retrospective study. What\'s more, we only focused on treatment mortality but not life quality in this analysis as the data of life quality were not provided by SEER.

Conclusions {#tca12794-sec-0013}
-----------

Compared with SA, NRT followed by resection had a significant survival benefit in non‐cervical EAC patients with T~3~N~+~ stage. For patients with ESCC and other EAC stages, NRT *versus* SA did not demonstrate a statistical significant survival difference.
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